Keyword: Viiv Healthcare

GlaxoSmithKline is rolling back its strict no-payments-to-doctors policy to allow some exceptions for select products and countries.

A cabotegravir/rilpivirine combo as a monthly HIV treatment showed similar efficacy to a standard three-drug therapy.

In Gilead's new TV awareness ads for HIV prevention, actors talk “honestly” about fearing HIV testing and having unprotected sex.

Gilead released data from a clinical trial showing that its new three-med HIV combo Biktarvy is noninferior to a treatment containing three GSK drugs.

After reporting a dismal hep C sales outlook, Gilead got a boost with an FDA nod for HIV combo Biktarvy, a drug with sales estimates of up to $10B.

Pharma is big on getting real patients to share their stories. Now, it’s starting to put those stories on the small screen.

ViiV Healthcare is taking its history in HIV treatment and community involvement to the small screen.

GlaxoSmithKline’s ViiV only just won its first two-drug HIV approval, but it's already bolstering its trial program.

GlaxoSmithKline’s two-drug HIV bet just paid off.

Healthcare professional ad agency McCann Echo has named Jesse Johanson president in a move that looks to the veteran to continue growing the agency.